JAMES B. BREITMEYER - 27 Jan 2022 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
27 Jan 2022
Net transactions value
+$42,080
Form type
4
Filing time
31 Jan 2022, 15:00:12 UTC
Previous filing
24 Jan 2022
Next filing
09 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Purchase $42,080 +25,000 +116% $1.68 46,544 27 Jan 2022 By Family Trust F1
holding ONCT Common Stock 384,149 27 Jan 2022 Direct
holding ONCT Common Stock 6,493 27 Jan 2022 By Spouse F2
holding ONCT Common Stock 733 27 Jan 2022 By Child
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.66 to $1.85. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above.
F2 This Form 4 corrects the number of RSUs awarded on January 3, 2022 held by the Reporting Person's spouse erroneously reported as 6,793 due to clerical error.